Growth Hormone & PerformanceGrade A
PT-141
Also known as Bremelanotide, Vyleesi
A melanocortin receptor agonist approved for hypoactive sexual desire disorder, acting centrally rather than vascularly.
- Regulatory status
- FDA approved (HSDD in premenopausal women)
- Half-life
- ~2.7 hours
- Route
- Subcutaneous autoinjector
- Evidence
- Multiple randomized controlled trials in humans
Mechanism of action
MC3R/MC4R agonism in the hypothalamus increasing sexual desire signaling.
Studied and reported uses
- Low sexual desire
- Erectile dysfunction (off-label)
Dosing information
Approved dose1.75 mg as needed, max 1 dose/24h
Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.
Side effects
- Nausea
- Flushing
- Headache
- Transient blood pressure increase
Research evidence
RECONNECT
Significant improvement in desire and distress scores.